Cerebral impairment in chronic solvent-induced encephalopathy

Annals of Neurology

Volumn 63, Issue 5, 2008, Pages 572-580

  Visser, Ieke ^a,b   Lavini, Cristina ^a   Booij, Jan ^a   Reneman, Liesbeth ^a   Majoie, Charles ^a   De Boer, Angela G E M ^b   Wekking, Elizabeth M ^a,c   De Joode, Elisabeth A ^a,b   Van Der Laan, Gert ^a,b   Van Dijk, Frank J H ^b   Schene, Aart H ^a   Den Heeten, Gerard J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Amsterdam Public Health research institute   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; SOLVENT;

ADULT; ARTICLE; ATTENTION; BRAIN DISEASE; BRAIN REGION; CHRONIC SOLVENT INDUCED ENCEPALOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BRAIN; CHEMICALLY INDUCED DISORDER; CHRONIC BRAIN DISEASE; COGNITIVE DEFECT; DRUG EFFECT; MALE; METABOLISM; MIDDLE AGED; OCCUPATIONAL DISEASE; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

BRAIN; BRAIN DAMAGE, CHRONIC; COGNITION DISORDERS; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL DISEASES; RECEPTORS, DOPAMINE D2; RETROSPECTIVE STUDIES; SOLVENTS;

EID: 44849093851     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21364     Document Type: Article

References (38)

1. White RF, Proctor SP. Solvents and neurotoxicity. Lancet 1997;349:1239-1243.
2. HSE. Health risks management: a guide to working with solvents HSG188. Sudburry, United Kingdom: Health and Safety Executive, 1998.
3. Current Intelligence Bulletin 48. Organic solvent neurotoxicity (DHHS Publ No. 87-104). Cincinnati, OH: USDHHS/PHS/CDC/NIOSH, 1987.
4. World Health Organization. Chronic effects of organic solvents on the central nervous system and diagnostic criteria (Environmental Health 5). Copenhagen: WHO, 1985:1-39.
5. World Health Organization. The ICD 10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.
6. American Psychiatric Association. Diagnostic and statistical manual for mental disorders, 4th ed. Washington, DC: American Psychiatric Press 1994.
7. Baker EL, White RF. Chronic effects of organic solvents on the central nervous system and diagnostic criteria. WHO (Copenhagen) and Nordic Council of Ministers (Oslo), reprinted by the US Department of Health and Human Services, Public Health Service, Washington, DC, 1985.
8. Baker EL. A review of recent research on health effects of human occupational exposure to organic solvents. J Occup Environ Med 1994;36:1079-1091.
9. Abjornsson G, Pallson B, Burgendorf U, et al. Long term follow-up of psychological distress, social functioning, and coping style in treated and untreated patients with solvent induced chronic toxic encephalopathy. J Occup Environ Med 1998;40:801-807.
10. Spurgeon A. The validity and interpretation of neurobehavioural data obtained in studies to investigate the neurotoxic effects of occupational exposure to mixtures of organic solvents. Birmingham, Health and Safety Executive Contract Research Report 355/2001. Birmingham: Health and Safety Executive, 2001.
11. Ridgway P, Nixon TE, Leach JP. Occupational exposure to organic solvents and long-term nervous system damage detectable by brain imaging, neurophysiology or histopathology. Food Chem Toxicol 2003;41:153-187.
12. Haut MW, Kuwara H, Ducatman AM, et al. Corpus callosum volume in railroad workers with chronic exposure to solvents. J Occup Environ Med 2006;48:615- 624.
13. Alkan A, Kutlu R, Hallac T, et al. Occupational prolonged organic solvent exposure in shoemakers: brain MR spectroscopy findings. Magn Reson Imaging 2004;22:707-713.
14. Aydin K, Sencer S, Kultekin O, et al. Single voxel proton spectroscopy in toluene abuse. Magn Reson Imaging 2003;21:777-785.
15. Euler von G. Toluene and dopaminergic transmission. In: Isaacson RL, Jensen KF, eds. The vulnerable brain and environmental risks, vol 3. Toxins in air and water. New York: Plenum Press, 1994:301-321.
16. Edling C, Hellman B, Arvidson B, et al. Do organic solvents induce changes in the dopaminergic system? Positron emission tomography studies of occupationally exposed subjects. Int Arch Occup Environ Health 1997;70:180-186.
17. Volkow ND, Gur RC, Wang GJ, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998;155:344-349.
18. Backman L, Ginovart N, Dixon RA, et al. Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am J Psychiatry 2000;157:635-637.
19. Lewis SJ, Dove A, Robbins TW, et al. Cognitive impairments in early Parkinson's disease are accompanied by reductions in activity in frontostriatal neural circuitry. J Neurosci 2003;23:6351-6356.
20. Blumberg HP, Martin A, Kaufman J, et al. Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry 2003;160:1345-1347.
21. Hoek van der JAF, Verberk MM, Laan G van der, Hageman G. A protocol for solvent induced CTE, 2 years of experience. Neurotoxicology 2000;21:887.
22. Schmand B, Bakker D, Saan R, Louman J. The Dutch Reading Test for Adults: a measure of premorbid intelligence level. Tijdschr Gerontol Geriatr 1999;22:15-19.
23. First MB, Gibbon M, Spitzer RL, Williams JBW. User guide for the Structured Clinical Interview for DSM IV axis I disorders. Washington, DC: American Psychiatric Association, 1996.
24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296.
25. Fahn S, Elton RL, and members of the UPDRS development committee Unified Parkinsons's Rating Scale. In: Fahn S, Marsden CD, Calne DB, Goldsein M, eds. Recent development in Parkinson's Disease. New York: Macmillan Healthcare Information, 1987:153-163.
26. Le Bihan D, Mangin JF, Poupon C, et al. Diffusion tensor imaging: concepts and applications. J Magn Reson Imaging 2001;13:534-546.
27. Hunsche S, Moseley ME, Stoeter P, Hedehus M. Diffusion-tensor MR imaging at 1.5 and 3.0 T: initial observations. Radiology 2001;221:550-556.
28. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672-679.
29. 123I]FP-CIT SPECT shows pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-140.
30. Wekking EM, van Hout MSE, Emmen HH. The Dutch neuropsychological test battery for diagnosing CTE, 2 years of experience. Neurotoxicology 2000;21:887-888.
31. Brand N, Wijk van der A, Hijman R. Motor planning in neurological and psychiatric patients. In: Drenth PJ, Sergeant JA, Takens RJ, eds. European perspectives in psychology. Chichester, United Kingdom: John Wiley, 2001:321-334.
32. 123I]IBZM has similar affinity to dopamine D2 and D3 receptors. Synapse 2000;38:338-342.
33. Murray AM, Ryoo HL, Gurevich E, Joyce JN. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 1994;91:11271-11275.
34. Jenkins BG, Kraft E. Magnetic resonance spectroscopy in toxic encephalopathy and neurodegeneration. Curr Opin Neurol 1991;12:753-760.
35. Martinez D, Gil R, Slifstein M, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005;58:779-786.
36. Newman J. Thalamic contributions to attention and consciousness. Conscious Cogn 1995;4:172-193.
37. Alexander GE, Crutcher MD, DeLong MR. Basal gangliathalamocortical circuits: parallel substrates for motor, occulomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990;85:119-146.
38. 11C]FLB 457. J Neurosci 2005;25:2471-2477.